Table 5.
Analysis of maximum likelihood estimates | ||||
---|---|---|---|---|
Variable | P-value | HR | 95% CI | |
(A) Overall population of patients with NSCLC | ||||
Age | <0.0001 | 1.45 | 1.032 | 1.058 |
Body mass index | 0.0500 | 0.977 | 0.955 | 1.000 |
Gender | ||||
F vs. M | 0.0035 | 0.709 | 0.563 | 0.893 |
ASA | ||||
2 vs. 4 | 0.0680 | 0.577 | 0.320 | 1.042 |
3 vs. 4 | 0.0163 | 0.598 | 0.392 | 0.910 |
Stage | ||||
I vs. III | <0.0001 | 0.481 | 0.358 | 0.648 |
II vs. III | 0.0495 | 0.736 | 0.543 | 0.999 |
Fentanyl equivalents | 0.2318 | 1.060 | 0.964 | 1.165 |
Preoperative radiation | ||||
N vs. Y | 0.0078 | 0.534 | 0.337 | 0.848 |
Postoperative radiation | ||||
N vs. Y | 0.0025 | 0.639 | 0.477 | 0.854 |
Thoracoscopy | ||||
N vs. Y | 0.0477 | 1.463 | 1.004 | 2.132 |
(B) Stage I | ||||
Age | <0.0001 | 1.051 | 1.029 | 1.073 |
Body mass index | 0.0026 | 0.939 | 0.902 | 0.978 |
Gender | ||||
F vs. M | <0.0001 | 0.422 | 0.286 | 0.622 |
ASA | ||||
2 vs. 4 | 0.0127 | 0.237 | 0.076 | 0.735 |
3 vs. 4 | 0.0216 | 0.508 | 0.285 | 0.906 |
Fentanyl equivalents | 0.0360 | 1.158 | 1.010 | 1.329 |
Postoperative radiation | ||||
N vs. Y | 0.0156 | 0.428 | 0.215 | 0.851 |
(C) Stage II | ||||
Age | <0.0001 | 1.057 | 1.030 | 1.084 |
Fentanyl equivalents | 0.5869 | 0.942 | 0.761 | 1.167 |
Preoperative radiation | ||||
N vs. Y | 0.0016 | 0.191 | 0.068 | 0.535 |
(D) Stage III | ||||
Age | 0.0442 | 1.022 | 1.001 | 1.043 |
LogFentanyl | 0.8621 | 0.986 | 0.839 | 1.158 |
Preoperative radiation | ||||
N vs. Y | 0.1439 | 0.661 | 0.379 | 1.152 |
Postoperative chemotherapy | ||||
N vs. Y | 0.0315 | 1.506 | 1.037 | 2.188 |